Pan-Bcl-2 Inhibitor AT-101 Enhances Tumor Cell Killing by EGFR Targeted T Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Nov 28

PMID 23185240

Citations 9

Authors

Archana Thakur

Lawrence G Lum

Dana Schalk

Asfar Azmi

Sanjeev Banerjee

Fazlul H Sarkar

Ramzi Mohommad

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is a deadly disease and has the worst prognosis among almost all cancers and is in dire need of new and improved therapeutic strategies. Conditioning of tumor cells with chemotherapeutic drug has been shown to enhance the anti-tumor effects of cancer vaccines and adoptive cell therapy. In this study, we investigated the immunomodulatory effects of pan-Bcl-2 inhibitor AT-101 on pancreatic cancer (PC) cell cytotoxicity by activated T cells (ATC). The effects of AT-101 on cytotoxicity, early apoptosis, and Granzyme B (GrzB) and IFN-γ signaling pathways were evaluated during EGFR bispecific antibody armed ATC (aATC)-mediated killing of L3.6pl and MiaPaCa-2 PC cells pre-sensitized with AT-101. We found that pretreatment of tumor cells with AT-101 enhanced susceptibility of L3.6pl and MiaPaCa-2 tumor cells to ATC and aATC-mediated cytotoxicity, which was in part mediated via enhanced release of cytolytic granule GrzB from ATC and aATC. AT-101-sensitized L3.6pl cells showed up-regulation of IFN-γ-mediated induction in the phosphorylation of Ser(727)-Stat1 (pS(727)-Stat1), and IFN-γ induced dephosphorylation of phospho-Tyr(705)-Stat3 (pY(705)-Stat3). Priming (conditioning) of PC cells with AT-101 can significantly enhance the anti-tumor activity of EGFRBi armed ATC through increased IFN-γ induced activation of pS(727)-Stat1 and inhibition of pY(705)-Stat3 phosphorylation, and resulting in increased ratio of pro-apoptotic to anti-apoptotic proteins. Our results verify enhanced cytotoxicity after a novel chemotherapy conditioning strategy against PC that warrants further in vivo and clinical investigations.

Citing Articles

Bioenergetic alteration in gastrointestinal cancers: The good, the bad and the ugly.

Chu Y, Chen C, Lai M, Lim S, Lin W World J Gastroenterol. 2023; 29(29):4499-4527.

PMID: 37621758 PMC: 10445009. DOI: 10.3748/wjg.v29.i29.4499.

Plant Polyphenol Gossypol Induced Cell Death and Its Association with Gene Expression in Mouse Macrophages.

Cao H, Sethumadhavan K Biomolecules. 2023; 13(4).

PMID: 37189372 PMC: 10136236. DOI: 10.3390/biom13040624.

Identification of as a Stably Expressed qPCR Reference Gene for Human Colon Cancer Cells Treated with Cottonseed-Derived Gossypol and Bioactive Extracts and Bacteria-Derived Lipopolysaccharides.

Cao H, Sethumadhavan K Molecules. 2022; 27(21).

PMID: 36364387 PMC: 9655230. DOI: 10.3390/molecules27217560.

Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma.

Mayer M, Berger A, Leischner C, Renner O, Burkard M, Bocker A Pharmaceuticals (Basel). 2022; 15(4).

PMID: 35455435 PMC: 9028974. DOI: 10.3390/ph15040438.

Gossypol decreased cell viability and down-regulated the expression of a number of genes in human colon cancer cells.

Cao H, Sethumadhavan K, Cao F, Wang T Sci Rep. 2021; 11(1):5922.

PMID: 33723275 PMC: 7961146. DOI: 10.1038/s41598-021-84970-8.

References

Radfar S, Wang Y, Khong H . Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. J Immunol. 2009; 183(10):6800-7. DOI: 10.4049/jimmunol.0901747. View

Arlen P, Gulley J, Parker C, Skarupa L, Pazdur M, Panicali D . A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res. 2006; 12(4):1260-9. PMC: 1526707. DOI: 10.1158/1078-0432.CCR-05-2059. View

Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K . Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006; 12(20 Pt 1):6116-24. DOI: 10.1158/1078-0432.CCR-06-0147. View

Reusch U, Sundaram M, Davol P, Olson S, Davis J, Demel K . Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res. 2006; 12(1):183-90. DOI: 10.1158/1078-0432.CCR-05-1855. View

Lake R, Robinson B . Immunotherapy and chemotherapy--a practical partnership. Nat Rev Cancer. 2005; 5(5):397-405. DOI: 10.1038/nrc1613. View

Tzeng C, Frolov A, Frolova N, Jhala N, Howard J, Vickers S . EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. J Surg Res. 2007; 143(1):20-6. DOI: 10.1016/j.jss.2007.01.051. View

Mohammad R, Wang S, Aboukameel A, Chen B, Wu X, Chen J . Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther. 2005; 4(1):13-21. View

Del Poeta G, Venditti A, Del Principe M, Maurillo L, Buccisano F, Tamburini A . Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood. 2002; 101(6):2125-31. DOI: 10.1182/blood-2002-06-1714. View

Ko H, Kim Y, Kim Y, Chang W, Ko S, Chang S . A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007; 67(15):7477-86. DOI: 10.1158/0008-5472.CAN-06-4639. View

10.

Sung B, Ravindran J, Prasad S, Pandey M, Aggarwal B . Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem. 2010; 285(46):35418-27. PMC: 2975165. DOI: 10.1074/jbc.M110.172767. View

11.

Eralp Y, Wang X, Wang J, Maughan M, Polo J, Lachman L . Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004; 6(4):R275-83. PMC: 468620. DOI: 10.1186/bcr787. View

12.

Antonia S, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N . Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006; 12(3 Pt 1):878-87. DOI: 10.1158/1078-0432.CCR-05-2013. View

13.

Osorio L, de Santiago A, Aguilar-Santelises M, Mellstedt H, Jondal M . CD6 ligation modulates the Bcl-2/Bax ratio and protects chronic lymphocytic leukemia B cells from apoptosis induced by anti-IgM. Blood. 1997; 89(8):2833-41. View

14.

Stark G, Kerr I, Williams B, Silverman R, Schreiber R . How cells respond to interferons. Annu Rev Biochem. 1998; 67:227-64. DOI: 10.1146/annurev.biochem.67.1.227. View

15.

Friess H, Kleeff J, Korc M, Buchler M . Molecular aspects of pancreatic cancer and future perspectives. Dig Surg. 1999; 16(4):281-90. DOI: 10.1159/000018737. View

16.

Grabert R, Cousens L, Smith J, Olson S, Gall J, Young W . Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res. 2006; 12(2):569-76. DOI: 10.1158/1078-0432.CCR-05-2005. View

17.

Loberg R, McGregor N, Ying C, Sargent E, Pienta K . In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia. 2007; 9(12):1030-7. PMC: 2134900. DOI: 10.1593/neo.07778. View

18.

Thakur A, Littrup P, Paul E, Adam B, Heilbrun L, Lum L . Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study. J Immunother. 2011; 34(5):457-67. PMC: 3893916. DOI: 10.1097/CJI.0b013e31821dcba5. View

19.

Fang P, Hwa V, Rosenfeld R . Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway. Exp Cell Res. 2006; 312(8):1229-39. DOI: 10.1016/j.yexcr.2005.12.011. View

20.

Mohammad R, Wang S, Banerjee S, Wu X, Chen J, Sarkar F . Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (-)-Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line. Pancreas. 2005; 31(4):317-24. DOI: 10.1097/01.mpa.0000179731.46210.01. View